Selected milestones from our work to build an open, end-to-end pharmaceutical system — from the lab bench to an open clinical trial.
OSPF has commenced a multicentric phase 2b clinical trial for an adjunct therapy for tuberculosis, reaching this stage nearly a decade faster and for roughly less than 1% the cost of conventional big pharma approaches. The initial 200+ patients have been enrolled, with all centers operative.
Multiple scientific papers have been published in international peer-reviewed academic journals, including the study protocol and results of our tuberculosis clinical trial.
Partnerships and collaborations with multiple scientific institutions have been formed across India, Europe and the United States.
View partnersOur tuberculosis trial is designed to be transparent from the protocol through to the data.
The Government of India's Chennai-based National Institute for Research in Tuberculosis (NIRT) is the primary sponsor and OSPF is the secondary sponsor. The trial has been prospectively registered on the Government of India clinical trials website, where the protocol can be viewed.
We have committed to making the IP from this trial open and placed in the public domain, and also to making data from the trial open. Generally, we will imbue clinical trials with open source methodologies to the maximum extent feasible — gradually at first and increasing over time.
Help advance open science through AI, global collaboration, and accessible healthcare. Volunteer or donate to make a lasting impact.
